Wells Fargo Maintains Overweight on Minimed Group, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 88.6%

Neg 88.6% Neu 0% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains Minimed Group (NASDAQ:MMED) with a Overweight and lowers the price target from $26 to $22.